Athebio enables its partners to develop next-generation therapeutics based on leading-edge designed ankyrin repeat proteins (DARPins) - the Athebody® DARPins.

Products, services, technology

Athebody® DARPins offer game-changing advantages for generating targeted therapeutics, including high stability, small size, reliable folding, excellent target affinity & specificity, species cross-reactivity, ease of generating multi-specificity, superb developability, and good FTO prospects.

Cooperation possibilities

We strive to enable our partners with repeat protein technology in the best possible way. This can range from giving access to our know-how & proprietary Athebody® DARPin technology, to selecting custom Athebody® DARPins or setting up an inhouse Athebody® DARPin selection machinery for our partners.

Location

Grabenstrasse 11A, 8952 Schlieren, Switzerland

Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2019
  • Number of employees in Switzerland
    10-19